In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes by Mayne, KJ, Herrington, WG

Bioimpedance in CKD: an untapped resource? by Mayne, KJ, Lees, JS, Herrington, WG

Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review by Mayne, KJ, Shemilt, R, Keane, DF, Lees, JS, Mark, PB, Herrington, WG

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD by Fletcher, RA, Herrington, WG, Agarwal, R, Mayne, KJ, Arnott, C, Jardine, MJ, Mahaffey, KW, Perkovic, V, Staplin, N, Wheeler, DC, Chertow, GM, Heerspink, HJL, Neuen, BL

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY by Nangaku, M, Herrington, WG, Goto, S, Maruyama, S, Kashihara, N, Ueki, K, Wada, J, Watada, H, Nakashima, E, Lee, R, Massey, D, Mayne, KJ, Tomita, A, Haynes, R, Hauske, SJ, Kadowaki, T

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial by Judge, PK, Tuttle, KR, Staplin, N, Hauske, SJ, Zhu, D, Sardell, R, Cronin, L, Green, JB, Agrawal, N, Arimoto, R, Mayne, KJ, Sammons, E, Brueckmann, M, Shah, SV, Rossing, P, Nangaku, M, Landray, MJ, Wanner, C, Baigent, C, Haynes, R, Herrington, WG

Long-term effects of empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R